Chiffres en millions de dollars américains. L'exercice financier va de février à janvier.
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Revenus
5,406
5,280
5,445
7,159
6,365
5,332
Croissance des revenus (H/H)
-1%
-3%
-24%
12%
19%
15%
Coût des ventes
3,722
3,532
4,501
4,863
4,367
3,300
Bénéfice brut
1,683
1,748
944
2,295
1,998
2,031
Vente, Général et Administration
862
781
930
972
878
767
Recherche et développement
257
203
173
244
216
154
Frais d'exploitation
1,344
1,099
1,232
1,292
1,186
996
Autres revenus (charges) non opérationnels
0
-14
-66
1
-4
-1
Bénéfice avant impôts
480
726
-928
829
222
1,327
Charge d'impôt sur le revenu
82
101
-126
114
-11
306
Bénéfice net
420
646
-783
727
240
1,024
Croissance du bénéfice net
-388%
-183%
-208%
202.99%
-77%
-3%
Actions en circulation (diluées)
1,467.29
1,467.29
1,467.29
1,467.29
1,467.29
1,467.3
Variation des actions (H-H)
0%
0%
0%
0%
0%
18%
EPS (dilué)
0.28
0.44
-0.53
0.49
0.16
0.7
Croissance du EPS
-387%
-183%
-208%
202%
-77%
-18%
Flux de trésorerie libre
1,685
1,991
-46
-979
-200
-175
Flux de trésorerie libre par action
--
--
--
--
--
--
Marge brute
31.13%
33.1%
17.33%
32.05%
31.39%
38.09%
Marge opérationnelle
6.27%
12.27%
-5.28%
14.01%
12.74%
19.41%
Marge bénéficiaire
7.76%
12.23%
-14.38%
10.15%
3.77%
19.2%
Marge du flux de trésorerie libre
31.16%
37.7%
-0.84%
-13.67%
-3.14%
-3.28%
EBITDA
--
744
-188
1,095
911
1,136
Marge EBITDA
--
14.09%
-3.45%
15.29%
14.31%
21.3%
D&A pour le résultat opérationnel
--
96
100
92
100
101
EBIT
339
648
-288
1,003
811
1,035
Marge EBIT
6.27%
12.27%
-5.28%
14.01%
12.74%
19.41%
Taux d'imposition effectif
17.08%
13.91%
13.57%
13.75%
-4.95%
23.05%
Statistiques clés
Clôture préc.
$0.4696
Prix d'ouverture
$0.4696
Plage de la journée
$0.4696 - $0.4696
Plage de 52 semaines
$0.4696 - $0.7206
Volume
25
Volume moyen
0
BPA (TTM)
-0.02
Rendement en dividend
--
Capitalisation boursière
$103.3M
Qu’est-ce que SHENZHEN HEPALINK PHARMACEUTICA ?
Shenzhen Hepalink Pharmaceutical Group Co Ltd is a CN-based company operating in Pharmaceuticals industry. The company is headquartered in Shenzhen, Guangdong and currently employs 1,926 full-time employees. The company went IPO on 2010-05-06. Shenzhen Hepalink Pharmaceutical Group Co Ltd is a China-based company primarily engaged in the heparin industry chain, contract development and manufacturing organization (CDMO) of biological macromolecules, and the investment, development, and commercialization of innovative drugs. The firm operates four segments. The Pharmaceutical Formulations segment manufactures and sells enoxaparin sodium injection and others. The Active Pharmaceutical Ingredients (APIs) segment manufactures and sells standard heparin APIs, enoxaparin APIs and others. The CDMO segment provides process development services for pharmaceutical intermediates and APIs, including process research, optimization, analytical testing, and formulation research. The Other segment engages in other product businesses, such as pancreatic enzymes and casings. The firm conducts its business in the domestic and overseas markets.